Citations

Clear

1792 citation(s) found for "Stephanie".

Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Mattison, Ryan J. , Abdelmessieh, Peter, Burke, Patrick W. , DeAngelo, Daniel J., Dinner, Shira, Fathi, Amir T. , Haddadin, Michael , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Long, Meixiao, Luger, Selina M. , Mangan, James K. , Massaro, Stephanie, May, William , Park, Jae H. , Schwartz, Marc S. , Shami, Paul J. , Tomlinson, Benjamin , Webster, Jonathan , Stehman, Katie, Shah, Bijal , Abboud, Ramzi , Aldoss, Ibrahim , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Jonas, Brian A. , Logan, Aaron C , Oluwole, Olalekan O. , Przespolewski, Amanda , Rangaraju, Sravanti , Saygin, Caner , Schwartz, Marc, Awotiwon, Ajibola

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 563-576

10.6004/jnccn.2024.0051 | PMID 39413812 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.
High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy
Han, Jianmin, Isom, Scott , Smith, Wesley, Begley, Stephanie, Jenneman, Dakota, Bose, Rupali, Seegars, Mary Beth, McCall, Chad M. , Hsi, Eric D. , Ghosh, Nilanjan

Mayo Clinic

Leukemia & Lymphoma | October 16, 2024 | Volume: 66 | Issue: 2 | Pages: 325-328

10.1080/10428194.2024.2414899 | PMID 39411845 Get It

Rethinking Measures and Mortality Attribution in Health Care: The ENT Example
Patel, Samip , Olivero, Lorenzo , FRÍAS, JORGE SINCLAIR DE , Anderson, Stephanie S., Pollock, Ben D., Lee, Marian D., Chirilă, Răzvan M. , Guru, Pramod , Pollock, Benjamin D. , Sinclair, Jorge Enrique , Guru, Pramod K , Taylor, Richard, Moreno Franco, Pablo , Patel, Samip N , Pollock, Benjamin D , Lee, Marian D., Murthy, Hemant S. , Taylor, Richard A. , Franco, Pablo Moreno , Menser, Terri

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 13, 2024 | Volume: 171 | Issue: 6 | Pages: 1925-1927

10.1002/ohn.1015 | PMID 39396155 Get It

AbstractNational performance metrics ultimately enhance patient decision‐making and promote meaningful improvements in health care delivery, which makes having valid and reliable measures essential. This study examined US News and World Report metrics from 2019 to 2012 and used electronic health record data, combined with detailed chart review across 3 in‐system hospitals, to assess the provision of care compared to the attribution of patients assigned to the ear, nose, and throat (ENT) mortality group. Of the initial 47 ENT‐attributed deaths, 23 of those were verified, dimensioning the mortality rate from 1.7% to just 0.8%. These results underscore the necessity of rethinking measures and mortality attribution methodologies to be more accurate. Current methods use Medicare Severity Diagnosis Related Group billing coding to map the attribution. We suggest transitioning away from specialty ranking approaches and towards a procedure and condition “rating” approach to ensure that these ranking types capture data about the provision of care within a given encounter.
Defining ideal middle cerebral artery bifurcation aneurysm size for Woven EndoBridge embolization
Adeeb, Nimer , Aslan, Assala , Alla, Anika, McLellan, Rachel , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Premat, Kévin, Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Tutino, Vincent M., Mohammed, Marwa A. , Özateş, Mehmet Özgür , Ayberk, Gıyas , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M, Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Sheth, Sunil G. , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Killer-Oberfalzer, Monika, Asadi, Hamed , Brook, Allan , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Cuellar-Saenz, Hugo H., Jabbour, Pascal , Patel, Aman B. , Tutino, Vincent M. , Ibrahim, Mohamed K. , Diestro, Jose Danilo B , Shotar, Eimad , Tutino, Vincent M , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Dibas, Mahmoud , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Premat, Kévin , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Domingo, Ricardo A. , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Essibayi, Muhammed Amir , Sheth, Sunil A., Tawk, Rabih G. , Panni, Pietro , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Limbucci, Nicola , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2024.5.jns232204 | PMID 39393093 Get It

OBJECTIVE The Woven EndoBridge (WEB) device was approved to treat wide-necked bifurcation aneurysms. The device is designed as an intrasaccular flow disruptor covering aneurysm widths up to 10 mm. Although prior studies combined all aneurysm sizes, it is known that aneurysms behave differently in response to endovascular treatment based on their size. Therefore, the authors’ objective was to identify ideal middle cerebral artery (MCA) aneurysm width and neck sizes most suitable for WEB treatment. METHODS The WorldWideWEB consortium is a large multicenter retrospective database that analyzes intracranial aneurysms treated with the WEB device. In this study, all unruptured MCA bifurcation aneurysms with available measurements were included. Cutoff values based on aneurysm width and neck in relation to aneurysm occlusion status were measured using the receiver operating characteristic (ROC) curve. Propensity score matching (PSM) was then used to compare treatment outcomes between aneurysms smaller and larger than the cutoff value for both width and neck size. RESULTS The ideal cutoff values for MCA bifurcation aneurysm width and neck were 6.1 mm and 4.6 mm, respectively. On PSM, 87 matched pairs were compared based on width size (≤ 6.1 mm and > 6.1 mm), and 77 matched pairs were compared based on neck size (≤ 4.6 mm and > 4.6 mm). There was a significant difference in adequate aneurysm occlusion between aneurysms smaller and larger than those cutoff values for both widths (93% vs 76%, p = 0.0017) and neck sizes (90% vs 70%, p = 0.0026). The retreatment rate was also significantly higher for larger aneurysms in both parameters. CONCLUSIONS This study shows that MCA bifurcation aneurysms ≤ 6.1 mm in width and ≤ 4.6 mm in neck size are significantly better candidates for WEB treatment, leading to improved occlusion status and reduced retreatment rate, which are important considerations when using WEB devices.
Conservative management of brain arteriovenous malformations: results of the prospective observation registry of a pragmatic trial
Gentric, Jean-Christophe, Heppner, Jonathan, Lopez, Camille, Jabre, Roland , Bojanowski, Michel W. , Chaalala, Chiraz , Januel, Anne-Christine, Sabatier, Jean-François, Desal, Hubert, Roualdes, Vincent , Alias, Quentin , Derrey, Stéphane , Gaberel, Thomas , Barbier, Charlotte , Barreau, Xavier , Anxionnat, René , Merlot, Isabelle, Nguyen, Thanh N., Abdalkader, Mohamad , Riva, Roberto, Troude, Lucas, Ollivier, Irène , Planty-Bonjour, Alexia, Chalumeau, Vanessa, Naggara, Olivier, Lefevre, Pierre-Henri, Corre, Marine Le, Carlson, Andrew P. , Thines, Laurent, Findlay, J. Max, Chabert, Emmanuel , Zehr, Justine , Klink, Ruby , Viard, Geraldine, Magro, Elsa, _, _, Raymond, Jean , Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Lopez, Camille, Ognard, Julien, Seizeur, Romuald, Pradier, Olivier, Boursier, Romain, Thillays, F. , Januel, Anne-Christine , Sabatier, Jean-François, Calvière, Lionel , Gauvrit, Jean‐Yves , Eugene, François, Boucherit, Julien , Lecouillard, Isabelle, Briens, Aurélien, Ronzière, Thomas , Trystram, D. , Naggara, Olivier , Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Bougaci, Nassim , Bracard, Serge, Civit, Thierry, Bernier‐Chastagner, Valérie , Penchet, Guillaume, Gimbert, Edouard, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard , Ifergan, Héloïse , Janot, Kévin, Brunel, Hervé, Roche, Pièrre-Hugues , Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Boissonneau, Sébastien , Clarençon, Frédéric , Premat, Kévin, Boch, Anne‐Laure , Cornu, Philippe, Nouet, Aurélien , Costalat, Vincent , Gascou, Gregory, Riquelme, Carlos, Pop, Raoul, Proust, François, Cébula, H. , Spatola, Giorgio, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Thouant, Pierre, Cao, Catherine, Mourier, Klaus-Luc, Farah, Walid, Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Miranda, Rodrigo Rivera, Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Ognard, Julien , Darsaut, Tim E. , Iancu, Daniela , Roy, Daniel C. , Weill, Alain , Comby, Pierre‐Olivier , Roberge, David , Cognard, Christophe , Desal, Hubert , Ferré, Jean‐Christophe , Papagiannaki, Chrysanthi , Smajda, Stanislas , Aldéa, Sorin , Marnat, Gaultier , Jecko, Vincent , Dumot, Chloé , Riva, Roberto , Graillon, Thomas , Troude, Lucas , Kerleroux, Basile , Beaujeux, Rémy , Boulouis, Grégoire , Spelle, Laurent , Chalumeau, Vanessa , Lefèvre, Pierre-Henri , Corre, Marine Le, Shotar, Eimad , Biondi, Alessandra , Tawk, Rabih G. , Huynh, Thien , Fahed, Robert , Gévry, Guylaine , _, _, O'Kelly, Cian J , Rempel, Jeremy L , Santos, Marlene dos, Gentric, Jean‐Christophe , Lopez, Camille, Nonent, Michel , Aouni, Mourad Cheddad El , Timsit, Serge , Piotin, Michel , Blanc, Raphaël , Morandi, Xavier , Vannier, Stéphane , Rodriguez-Régent, Christine , Touzé, Emmanuel , Eker, Omer , Charbonnier, Guillaume , Gory, Benjamin , Velut, Stéphane , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Corre, Marine Le, Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Nguyen, Thanh N. , Silva, Gisele Sampaio , Montalverne, Francisco Jose , Mendes, George Nilton Nunes

Mayo Clinic

Journal of Neurosurgery | October 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2024.5.jns24623 | PMID 39393100 Get It

OBJECTIVE Many patients recruited in the Treatment of Brain Arteriovenous Malformations Study (TOBAS) are managed conservatively. The aim of this study was to monitor what happened to those patients. METHODS TOBAS comprises two randomized controlled trials and multiple prospective registries. All patients with brain arteriovenous malformations (AVMs) can participate. This report concerns patients selected for conservative management. The primary trial outcome measure is related death or dependency (modified Rankin Scale [mRS] score > 2) at 10 years. Secondary outcomes include intracranial hemorrhages, nonhemorrhagic neurological events, and serious adverse events (SAEs). For this report, outcome results are presented using patient-years, Kaplan-Meier survival curves, and Cox log-rank tests. There was no blinding. RESULTS From June 2014 to May 2021, 1010 patients were recruited, of whom 498 (49%) were proposed the prospective observation registry. After exclusions, 434 (87%) patients remained for analysis. The majority of patients had unruptured AVMs (378/434 [87%]), of which 195 (52%) were low grade (Spetzler-Martin grade I or II). During a mean follow-up period of 3.2 years (total 1368 patient-years), the primary outcome occurred in 23 of 434 (5%) patients, corresponding to an incidence of 1.7 (95% CI 1.1–2.5) per 100 patient-years. For unruptured AVMs the incidence was 1.1 (95% CI 0.7–1.9) per 100 patient-years, and for low-grade unruptured AVMs it was 0.6 (95% CI 0.2–1.7) per 100 patient-years. Poor outcomes were more frequent in patients with a history of rupture (HR 5.6 [95% CI 2.4–13.0], p < 0.001), infratentorial AVMs (HR 2.9 [95% CI 1.1–7.3], p = 0.027), and age ≥ 55 years (HR 3.2 [95% CI 1.4–7.6], p = 0.007). Major intracranial hemorrhage occurred in 35 of 434 (8%) patients (incidence of 2.6 [95% CI 1.9–3.6] per 100 patient-years; 2.0 [95% CI 1.3–2.9] per 100 patient-years for unruptured AVMs and 1.3 [95% CI 0.6–2.6] per 100 patient-years for low-grade unruptured AVMs). Major AVM hemorrhages were more frequent in ruptured (HR 4.4 [95% CI 2.1–8.9], p < 0.001), large (HR 2.6 [95% CI 1.1–6.6], p = 0.039), and high-grade (HR 2.5 [95% CI 1.2–5.3], p = 0.013) AVMs and those with deep venous drainage (HR 2.1 [95% CI 1.1–4.2], p = 0.032). SAEs occurred in 48 of 434 (11%) patients (incidence of 3.6 [95% CI 2.7–4.8] per 100 patient-years). For unruptured AVMs the incidence was 2.8 (95% CI 2.0–4.0) per 100 patient-years, and for low-grade unruptured AVMs it was 1.8 (95% CI 1.0–3.2) per 100 patient-years. CONCLUSIONS Nearly half of TOBAS participants were observed. Rates of untoward neurological events were within expected boundaries.
Implementation and validation of face de‐identification (de‐facing) in ADNI4
Schwarz, Christopher G., Choe, Mark, Rossi, Stéphanie, Ittyerah, Ranjit, Fletcher, Evan, Maillard, Pauline , Singh, Baljeet , Harvey, Danielle , Malone, Ian B., Prosser, Lloyd , Matoush, Leonard, Ward, Chadwick P., Prakaashana, Carl M., Landau, Susan, Lee, JiaQie, DeCarli, Charles , Weiner, Michael W. , Jack, Clifford R. , Jagust, William, Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , Malone, Ian B. , Matoush, Leonard C, Jack, Clifford R , Harvey, Danielle J , Tosun, Duygu , Maillard, Pauline , Schwarz, Christopher G. , Rossi, Stephanie, Das, Sandhitsu R. , Senjem, Matthew L. , Koeppe, Robert A. , Yushkevich, Paul A. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 11, 2024 | Volume: 20 | Issue: 11 | Pages: 8048-8061

10.1002/alz.14303 | PMID 39392215 Get It

AbstractINTRODUCTIONRecent technological advances have increased the risk that de‐identified brain images could be re‐identified from face imagery. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a leading source of publicly available de‐identified brain imaging, who quickly acted to protect participants’ privacy.METHODSAn independent expert committee evaluated 11 face‐deidentification (“de‐facing”) methods and selected four for formal testing.RESULTSEffects of de‐facing on brain measurements were comparable across methods and sufficiently small to recommend de‐facing in ADNI. The committee ultimately recommended mri_reface for advantages in reliability, and for some practical considerations. ADNI leadership approved the committee's recommendation, beginning in ADNI4.DISCUSSIONADNI4 de‐faces all applicable brain images before subsequent pre‐processing, analyses, and public release. Trained analysts inspect de‐faced images to confirm complete face removal and complete non‐modification of brain. This paper details the history of the algorithm selection process and extensive validation, then describes the production workflows for de‐facing in ADNI.Highlights ADNI is implementing “de‐facing” of MRI and PET beginning in ADNI4. “De‐facing” alters face imagery in brain images to help protect privacy. Four algorithms were extensively compared for ADNI and mri_reface was chosen. Validation confirms mri_reface is robust and effective for ADNI sequences. Validation confirms mri_reface negligibly affects ADNI brain measurements.
Prenatal Ultrasonographic Features Associated With ARSL and X‐Linked Chondrodysplasia Punctata 1 (CDPX1): Literature Review and Case Series
Broeren, Eleanor , Stover, Samantha, Bennett, Katya, Giordano, Jessica L. , Galloway, Stephanie, Lauzon, Julie, Rust, Laura, Suerink, Manon , Haeringen, Arie van , Team, Australian Genomic Autopsy Study, Reimers, Rebecca, Giordano, Jessica , Broeren, Eleanor C , Stover, Samantha R. , Team, Australian Genomic Autopsy Study, Reimers, Rebecca

Mayo Clinic

Prenatal Diagnosis | October 8, 2024 | Volume: 44 | Issue: 13 | Pages: 1663-1670

10.1002/pd.6649 | PMID 39313411 Get It

ABSTRACT Background Chondrodysplasia punctata 1 (CDPX1) is an X‐linked recessive disorder of cartilage and bone development characterized by stippling on the cartilage and bone, flattened nasal bridge, and brachydactyly, or short fingers. CDPX1 has been associated with variants in the ARSL gene and is known to manifest prenatally, however, there has been no systematic literature review on this evidence. Aims Here, we reviewed the current literature on prenatal manifestations of CDPX1, and additionally introduce previously unpublished cases. Materials & Methods A systematic review of the literature was performed. Additionally, a GeneMatcher submission was created and a call for cases was presented at the Fetal Sequencing Consortium meetings to find previously unpublished cases. Results For the 22 fetuses reported here, we found that 55% had nasal hypoplasia, 41% had bony stippling or calcifications, 32% had polyhydramnios, 5% had oligohydramnios, 23% had shortened long bones, 23% had spinal canal stenosis, 18% had ventriculomegaly, 9% had brachydactyly/brachytelephalangy, 9% had clubbed feet, 9% had premature rupture of membranes, and 9% had intraventricular hemorrhage detected through sonography or radiography. We also found 17 unique variants in ARSL for these 22 fetuses. Discussion A previously unpublished association of ARSL variants with intrauterine fetal death or stillbirth has been noted in this study. It is also possible that intracranial hemorrhage is an underrecognized feature associated with CDPX1 variation. However, there have been challenges in applying ACMG criteria to ARSL, a gene without an associated Variant Curation Expert Panel. Conclusion This literature review and case series highlights which features of CDPX1 manifest prenatally, as well as introduces new phenotypes that have not been previously identified.
Microsurgical Treatment of Intracranial Dural Arteriovenous Fistulas: A Collaborative Investigation From the Multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research
Raygor, Kunal P. , Abdelsalam, Ahmed , Raper, Daniel , Guniganti, Ridhima , Durnford, Andrew , Brinjikji, Waleed , Abecassis, Isaac Josh, Polifka, Adam , Samaniego, Edgar A. , Kwasnicki, Amanda , Potgieser, Adriaan R. E., Tada, Yoshiteru , Kansagra, Akash P. , Satomi, Junichiro, Eatz, Tiffany , Peterson, Eric C. , Starke, Robert M., Dijk, J. Marc C. van , Hayakawa, M. , Gross, Bradley A. , Fox, W. Christopher, Kim, Louis J. , Sheehan, Jason , Bulters, Diederik , Zipfel, Gregory J. , Abla, Adib A. , Alaraj, Ali , Eatz, Tiffany , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Tonetti, Daniel A. , Giordan, Enrico , Chen, Ching‐Jen , Levitt, Michael R. , Derdeyn, Colin P. , Chen, Stephanie , Peterson, Eric C., Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Lanzino, Giuseppe , Du, Rose , Lai, Pui Man Rosalind

Mayo Clinic

Neurosurgery | October 8, 2024 | Volume: 96 | Issue: 5 | Pages: 1023-1034

10.1227/neu.0000000000003204 | PMID 39471093 Get It

BACKGROUND AND OBJECTIVES: First-line therapy for most intracranial dural arteriovenous fistulas (dAVFs) is endovascular embolization, but some require microsurgical ligation due to limited endovascular accessibility, anticipated lower cure rates, or unacceptable risk profiles. We investigated the most common surgically treated dAVF locations and the approaches and outcomes of each. METHODS: The Consortium for Dural Arteriovenous Fistula Outcomes Research database was retrospectively reviewed. Patients who underwent dAVF microsurgical ligation were included. Patient demographics, angiographic information, surgical details, and postoperative outcomes were collected. The 5 most common surgically treated dAVF locations were analyzed about used surgical approaches and postoperative outcomes. Univariate analyses were performed with statistical significance set at a threshold of P < .05. RESULTS: In total, 248 patients in the Consortium for Dural Arteriovenous Fistula Outcomes Research database met inclusion criteria. The 5 most common surgically treated dAVF locations were tentorial, anterior cranial fossa (ACF), transverse-sigmoid sinus (TSS), convexity/superior sagittal sinus (SSS), and torcular. Most tentorial dAVFs were approached using a suboccipital, lateral supracerebellar infratentorial approach (39.3%); extended retrosigmoid approach (ERS) (25%); or posterior subtemporal approach (19.6%). All ACF dAVFs used a subfrontal approach; 5.3% also included an anterior interhemispheric approach. Most TSS dAVFs were ligated via ERS (31.3%) or subtemporal (31.3%) approaches. All convexity/SSS dAVFs used an interhemispheric approach. All torcular dAVFs used the suboccipital, lateral supracerebellar infratentorial approach, with 10.5% undergoing simultaneous ERS craniotomy. Angiographic occlusion rates after microsurgery were 85.5%, 100%, 75.8%, 79.2%, and 73.7% for tentorial, ACF, TSS, convexity/SSS, and torcular dAVFs, respectively ( P = .02); the permanent neurological complication rates were 1.8%, 2.6%, 9.1%, 0%, and 0% ( P = .31). There were no statistically significant differences in development of complications ( P = .08) or Modified Rankin Scale at the last follow-up ( P = .11) by fistula location. CONCLUSION: Although endovascular embolization is the first-line treatment for most intracranial dAVFs, surgical ligation is an important alternative. ACF and tentorial fistulas particularly demonstrate high rates of postoperative obliteration.
7204 An Unexpected Cause of Ga-68 Dotatate PET/CT Somatostatin Receptor Avidity in a Pediatric Patient with Hereditary Paraganglioma-Pheochromocytoma Syndrome due to an SDHA Mutation
Leopold, Kaitlin , Binkovitz, Larry A. , Casas, Luis Domingo Guerra, Lteif, Aida, Polites, Stephanie F. , Casas, Luis

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.1408 Get It

Abstract Disclosure: K. Leopold: None. S. Polites: None. L. Binkovitz: None. L. Casas: None. A.N. Lteif: None. Title: An Unexpected Cause of Ga-68 Dotatate PET/CT Somatostatin Receptor Avidity in a Pediatric Patient with Hereditary Paraganglioma-Pheochromocytoma Syndrome due to an SDHA Mutation. Introduction: Individuals with Succinate Dehydrogenase (SDHx) gene mutations have an increased risk of paragangliomas and pheochromocytomas beginning in childhood.Clinical Case: A 9 year old male with Cornelia de Lange syndrome and a paternally inherited SDHA pathogenic gene variant (c1534C&gt;T) presented with worsening migraine headaches and skin pallor with activity. 24 hour urine fractionated metanephrines were mildly elevated, with metanephrine 122 mcg/24h (29-92 mcg/24 h), normetanephrine 187 mcg/24 h (34-169 mcg/24 h), and total metanephrine 309 mcg/24 h (47-223 mcg/24 h). Ga-68 DOTATATE PET/CT showed a focus of moderately increased radiotracer activity in the anterior aspect of the distal gastric antrum with a max SUV 8.2 corresponding to a 9x7 mm nodule on CT in the same area, suggestive of underlying somatostatin receptor positive lesion such as a paraganglioma. MRI with contrast completed to further characterize the lesion showed no visible mass corresponding to the focal area of radiotracer uptake on DOTATATE PET/CT. Repeat 24 h urine metanephrines continued to show mild elevation of metanephrine (138 mcg/24h), normetanephrine (200 mcg/24h), and total metanephrines (338 mcg/24h). 24 hour urine catecholamines, 5-Hydroxyindoleacetic acid, and homovanillic acid were normal. An upper endoscopic ultrasound was completed which confirmed the presence of a lesion near the stomach but not arising from the stomach wall and not consistent with a gastrointestinal stromal tumor. CT enterography with IV contrast showed a 6x6 mm enhancing mass within the distal right lateral gastric wall. Due to ongoing symptoms, mild elevations in urine fractionated metanephrines, and a clear mass on US and CT, the patient underwent laparoscopic abdominal exploration where a 14x14x13 mm mass with surrounding gastric and duodenal serosa was excised with primary closure of the bowel. Pathology showed ectopic pancreatic tissue in the wall of the small bowel and stomach. Repeat Ga-68 DOTATATE PET/CT 5 months following surgery showed resolution of the distal gastric somatostatin receptor avidity. Clinical Lesson: This is the first case of ectopic pancreatic tissue mimicking a paraganglioma in a pediatric patient with hereditary paraganglioma-pheochromocytoma syndrome. False positive imaging should be considered in patients with SDHx mutations when the uptake is atypical in location and when the elevation in urine metanephrines is mild. Presentation: 6/3/2024
7590 Bone Mineral Content In Women With Functional Hypothalamic Amenorrhea Compared To Eumenorrheic Controls And Recently Menopausal Women
Safwan, Nancy , Uddenberg, Erin R, Hurtado, M D, Saadedine, Mariam , Obrutu, Okezi, Berga, Sarah L. , Pisarska, Margareta D. , Faubion, Stephanie S. , Merz, C. Noel Bairey , Shufelt, Chrisandra

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.368 Get It

Abstract Disclosure: N. Safwan: None. E.R. Uddenberg: None. M.D. Hurtado: None. M. Saadedine: None. S.S. Faubion: None. O. Obrutu: None. S.L. Berga: None. M.D. Pisarska: None. C. Bairey Merz: None. C.L. Shufelt: None. Background: Functional hypothalamic amenorrhea (FHA) accounts for 30% of secondary amenorrhea due to suppression of GnRH associated hypercortisolemia resulting in chronic hypoestrogenemia. FHA occurs as a result of varying combinations of psychosocial stress, excessive exercise, and/or disordered eating. FHA is associated with decreased bone mineralization; however, it is unknown how bone health compares to older, menopausal women who also experience bone loss. We compared dual-energy x-ray absorptiometry (DXA) bone health parameters among women with FHA, eumenorrheic controls, and recently menopausal women and evaluated if previous oral contraceptive (OC) use among FHA women has an impact on bone mineral density (BMD). Methods: This cross-sectional study included 20 women with FHA, 9 eumenorrheic controls, and 12 recently menopausal women who underwent hip and spine DXA. All participants were not on hormone therapy. FHA was defined as amenorrhea &gt;3 consecutive months, estradiol &lt;50 pg/ml, FSH &lt;10 mIU/L, and LH &lt;10 mIU/L, excluding other etiologies including PCOS, prolactinoma, thyroid dysfunction, and pregnancy. Eumenorrheic controls had self-reported monthly menses confirmed with day 22-24 progesterone &gt;3 ng/ml. Recently menopausal women had natural menopause &lt;3 years of final menstrual period, and FSH &gt;30 mIU/L. DXA bone health parameters were measured using Lunar iDXA (GE) including BMD from the lumbar spine (L1-L4) and hip. Statistical analysis included nonparametric testing with pairwise Wilcoxon rank sum and Kruskal Wallis, reported as median [interquartile ranges]. Results: By design, the mean age of FHA was 28 ± 6 yr, 29 ± 3 yr for controls, and 54 ± 2 yr for recently menopausal women (p&lt;0.0001). There were no differences in weight or BMI among the groups (p=0.27, p=0.30, respectively). BMD L1-L4 differed among the three groups with 1.10 g/cm2 [1.00, 1.24] for FHA, 1.18 [1.15, 1.29] for eumenorrheic controls, and 1.02 [0.96, 1.08] for menopausal women (p=0.002). Pairwise analysis revealed a significant difference in BMD L1-L4 between FHA and controls (p=0.04) and menopausal women and controls (p=0.009, age-adjusted). However, there was no difference in BMD L1-L4 between FHA and menopausal women (p=0.08, age-adjusted). In FHA women with previous OC use, BMD L1-L4 was not different from eumenorrheic controls (p=0.20), while BMD L1-L4 differed from that of recently menopausal women (p=0.004). These differences were not observed at the hip. Conclusion: Compared to eumenorrheic controls, lumbar spine BMD in young women with FHA (mean age 28 yr) was similar to recently menopausal women (mean age 54 yr) emphasizing the profound bone impact of FHA. Previous OC use seems to mitigate FHA bone mineralization changes. Future studies should investigate if bone health differs among women with FHA based on underlying cause and if previous OC use plays a role in maintaining bone health. Presentation: 6/3/2024